(A) Flow cytometry analysis of apoptosis in A375 and skmel-5 cells after treatment with ALS, p38 MAPK siRNA, or p38 MAPK siRNA + ALS for 24 hours; (B) Flow cytometry analysis of autophagy in A375 and skmel-5 cells after treatment with ALS, p38 MAPK siRNA, or p38 MAPK siRNA + ALS for 24 hours; (C) Quantification of apoptotic A375 and skmel-5 cells after treatment with ALS, p38 MAPK siRNA, or p38 MAPK siRNA + ALS; (D) Quantification of autophagic A375 and skmel-5 cells after treatment with ALS, p38 MAPK siRNA, or p38 MAPK siRNA + ALS; (E) Western blot analysis of the levels of cleaved caspase-3, cleaved PARP, LC3-I, and LC3-II in A375 and skmel-5 cells after treatment with ALS, p38 MAPK siRNA, or p38 MAPK siRNA + ALS; (F) Quantification of the relative protein levels. Data are expressed as the means ± SD. All experiments were repeated at least three times. (*p < 0.05, **p < 0.01, ***p < 0.001).